



Press release from Emotra AB (publ)

Göteborg, July 30, 2018

## **Emotra is granted a patent in Japan**

**As we have previously announced, Japan is one of Emotra's high-priority markets. The company has applied for patents in the EU, USA, Canada and Japan. The Japanese patent office has now informed us that Emotra's Japanese patent application number 2016-516080 has been approved.**

The Japanese patent office has informed Emotra that our Japanese patent application number 2016-516080, "A DEVICE FOR USE IN THE EVALUATION OF SUICIDE RISK", has been approved. Our patent has already been approved by the Swedish Patent and Registration Office, PRV. The company is still awaiting similar news from other patent offices, since they are still processing our applications.

### **Claes Holmberg, Emotra's CEO, states:**

*"The fact that our patent has now been approved in yet another country is an important milestone for Emotra. We have not yet seen any significant objections to our patent applications from any patent office. Certain remarks from the US Patent and Trademark Office have given us reason to make minor adjustments of our first patent requirement, but otherwise the process in the various countries seems to be progressing as planned. At present, our focus is on getting started in a number of major European cities, but further on the USA, Japan and Canada will be important markets for our method."*

**For further information, please contact:** Claes Holmberg, CEO. Telephone: +46 708 25 45 47, E-mail: [claes@emotra.se](mailto:claes@emotra.se)

*This information is the type of information that Emotra AB is legally obliged to publish in accordance with the EU market abuse regulation. This information was submitted for publication on July 30, 2018 under the above contact's supervision.*

---

**Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR<sup>®</sup>, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 88, SE-433 63 Sävedalen, Sweden

Tel: +46 708 25 45 47, [www.emotra.se](http://www.emotra.se)